NASDAQ : IRWD
Ironwood Pharmaceuticals, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 3.62 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 598.17M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 578.34M |
| Enterprise Value | 896.08M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 165.24M |
| Shares Outstanding | 165.24M |
| Shares Change (YoY) | +3.27% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 3.24% |
| Owned by Institutions (%) | 82.77% |
| Float | 136.76M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 4.39 |
| Forward PE | 2.76 |
| PS Ratio | 1.49 |
| Forward PS | 1.22 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 3.12 |
| P/OCF Ratio | 3.12 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 6.90 |
| EV / Sales | 2.30 |
| EV / EBITDA | 3.76 |
| EV / EBIT | 3.79 |
| EV / FCF | 4.83 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.06 |
| Quick Ratio | 5.84 |
| Debt / Equity | n/a |
| Debt / EBITDA | 1.65 |
| Debt / FCF | 2.14 |
| Interest Coverage | 7.23 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 47.02% |
| Return on Invested Capital (ROIC) | 65.68% |
| Return on Capital Employed (ROCE) | 93.66% |
| Weighted Average Cost of Capital (WACC) | 5.34% |
| Revenue Per Employee | $3.89M |
| Profits Per Employee | $1.30M |
| Employee Count | 100 |
| Asset Turnover | 1.24 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 77.51M |
| Effective Tax Rate | 37.38% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.22 |
| 52-Week Price Change | +80.21% |
| 50-Day Moving Average | 3.94 |
| 200-Day Moving Average | 3.98 |
| Relative Strength Index (RSI) | 39.11 |
| Average Volume (20 Days) | 1,623,319 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 15.89M |
| Short Previous Month | 15.57M |
| Short % of Shares Out | 9.61% |
| Short % of Float | 11.62% |
| Short Ratio (days to cover) | 7.16 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 389.32M |
| Gross Profit | 300.62M |
| Operating Income | 236.27M |
| Pretax Income | 207.38M |
| Net Income | 129.87M |
| EBITDA | 238.11M |
| EBIT | 236.27M |
| Earnings Per Share (EPS) | $0.79 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 79.13M |
| Total Debt | 396.87M |
| Net Cash | -317.74M |
| Net Cash Per Share | -$1.92 |
| Equity (Book Value) | -161.84M |
| Book Value Per Share | -0.98 |
| Working Capital | 166.35M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 185.56M |
| Capital Expenditures | -1,000 |
| Depreciation & Amortization | 1.84M |
| Net Borrowing | -200.00M |
| Free Cash Flow | 185.55M |
| FCF Per Share | $1.12 |
Margins
| Measure | Value |
|---|
| Gross Margin | 77.22% |
| Operating Margin | 60.69% |
| Pretax Margin | 53.27% |
| Profit Margin | 33.36% |
| EBITDA Margin | 61.16% |
| EBIT Margin | 60.69% |
| FCF Margin | 47.66% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.27% |
| Shareholder Yield | -3.27% |
| Earnings Yield | 22.80% |
| FCF Yield | 32.08% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $6.10 |
| Price Target Difference | 76.30% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 19.11% |
| EPS Growth Forecast (3Y) | 83.97% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -2.34 |
| Piotroski F-Score | 7 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | n/a |
| Graham Upside | n/a |